H.R. 9462

H.R. 9462: To amend the Securities Exchange Act of 1934 to prohibit mandatory pre-dispute arbitration agreements, and for other purposes.

Introduced Bill Foster (D) HOUSE_BILL — 119th Congress
Plain English Summary

H.R. 9462 aims to amend the Securities Exchange Act of 1934 to prohibit the use of mandatory pre-dispute arbitration agreements in securities transactions. This means that individuals would not be required to resolve disputes through arbitration before a legal issue arises, allowing them to pursue litigation in court instead.

Positive Media Summary

Supporters of H.R. 9462 argue that the bill enhances consumer protection by ensuring that investors have the right to take their disputes to court, which can lead to more transparent and fair resolutions. Advocates believe this will empower individuals and promote accountability among financial institutions.

Negative Media Summary

Critics of H.R. 9462 contend that eliminating mandatory arbitration could lead to increased litigation costs and a backlog in the court system, ultimately harming both investors and companies. Some argue that arbitration is a faster and more efficient way to resolve disputes than traditional court proceedings.

Conflict of Interest Analysis Deep Analysis
2/10
Risk Level
Low
Total Donations
$0
PAC Percentage
0%
Policy Area
Finance and Financial Sector

The analysis of H.R. 9462, which aims to prohibit mandatory pre-dispute arbitration agreements, reveals no direct industry overlaps between the sponsor Bill Foster's top donor industries and the bill's subject matter. The lobbying activity in this policy area includes significant contributions from Vertex Pharmaceuticals ($60,000) and Smart Approaches to Marijuana ($20,000), among others, but these do not directly relate to the subject of arbitration agreements. The lack of direct financial ties suggests that there is minimal risk of conflicts of interest impacting the legislative process. Voters should be aware that while lobbying exists, it does not appear to influence the bill's intent or the sponsor's motivations significantly.

Lobbying Activity — Who's Pushing?

Organizations that lobbied on issues related to this bill's policy area.

Client Lobbying Firm Amount
VERTEX PHARMACEUTICALS INCORPORATED MARSHALL & POPP, LLC $60,000
SUN PHARMACEUTICAL INDUSTRIES, INC. MARSHALL & POPP, LLC $60,000
SANOFI U.S. SERVICES, INC. MARSHALL & POPP, LLC $60,000
WAYFINDER GROUP (OBO RESEARCH CORPORATION OF THE UNIVERSITY OF HAWAII) RED MAPLE CONSULTING, LLC $40,000
ECKERD CONNECTS KOUNTOUPES DENHAM CARR & REID, LLC $30,000
SMART APPROACHES TO MARIJUANA OFF HILL STRATEGIES L.L.C. $20,000
FEDERATION OF ELECTRIC POWER COS OF JAPAN GEORGE H. DENISON $10,000
MAYO CLINIC MCDERMOTT WILL & SCHULTE LLP undisclosed
VERIZON COMMUNICATIONS, INC. MARSHALL & POPP, LLC undisclosed
THE BIG TEN CONFERENCE, INC. MARSHALL & POPP, LLC undisclosed
THE BIG 12 CONFERENCE, INC. MARSHALL & POPP, LLC undisclosed
SOUTHEASTERN CONFERENCE MARSHALL & POPP, LLC undisclosed
PAC-12 CONFERENCE MARSHALL & POPP, LLC undisclosed
ATLANTIC COAST CONFERENCE MARSHALL & POPP, LLC undisclosed
SAPPHIRE DIGITAL MARSHALL & POPP, LLC undisclosed

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

Sponsor's Top Donor Industries

Top industries funding Bill Foster, ranked by total contributions.

Health Professionals $240,000,000
Individuals: $240,000,000 PACs: $0
Retired $75,000,000
Individuals: $75,000,000 PACs: $0

Source: OpenSecrets.org (Center for Responsive Politics)

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us